{ }
Very Negative
Negative
Neutral
Positive
Very Positive
2025-04-192025-04-192025-04-202025-04-202025-04-212025-04-212025-04-222025-04-222025-04-232025-04-232025-04-242025-04-24112141419971211282424181812126600
Download SVG
Download PNG
Download CSV
Somewhat Relevant
Moderately Relevant
Very Relevant
Highly Relevant
2025-04-192025-04-192025-04-202025-04-202025-04-212025-04-212025-04-222025-04-222025-04-232025-04-232025-04-242025-04-2413511643143126101122424181812126600
Download SVG
Download PNG
Download CSV

UBS lowers L'Oreal price target amid expectations of weak third quarter

UBS has reduced its price target for L'Oréal from 440 to 415 euros while maintaining a "Neutral" rating. Analyst Guillaume Delmas anticipates a weak third quarter for the cosmetics group, following disappointing sales figures from luxury goods giant LVMH.
22:30 15.10.2024

LVMH reports strong global sales across luxury product categories

LVMH Moët Hennessy Louis Vuitton SE, a leader in luxury products, generates net sales primarily from fashion and leather goods (48.9%), followed by watches and jewelry (12.8%), perfumes and cosmetics (9.6%), and wines and spirits (7.7%). The company operates 6,097 stores globally, with significant sales in Asia (30.8%) and the United States (25.3%).
21:35 15.10.2024

ubs rates lvmh neutral with target price of 660 euros

UBS has rated LVMH Moët Hennessy Louis Vuitton SE as 'Neutral' with a target price of 660 euros. The luxury giant's net sales are primarily driven by fashion and leather goods (48.9%), followed by watches and jewelry (12.8%), perfumes and cosmetics (9.6%), and wines and spirits (7.7%). Geographically, sales are concentrated in Asia (30.8%) and the United States (25.3%), with a global distribution network of 6,097 points of sale by the end of 2023.
21:35 15.10.2024

UBS maintains neutral stance on LVMH with target price of 660 euros

UBS has maintained a "Neutral" rating on LVMH with a target price of 660 euros following disappointing third-quarter sales, particularly in the crucial fashion and leather goods division. Analyst Zuzanna Pusz expressed concerns over the group's performance in her initial reaction.
20:48 15.10.2024

pharmaceutical stocks to consider for income and growth potential

Argus has issued "buy" ratings for several pharmaceutical stocks, including Sanofi (SNY) with a $60 price target, Gilead Sciences (GILD) at $85, and GSK at $45. The sector is projected to grow significantly, driven by oncology sales, with companies like Johnson & Johnson and Merck also highlighted for their strong pipelines and dividend yields.

franco quebec collaboration drives healthcare innovation and sustainability in systems

Franco-Quebec exchanges in healthcare innovation are crucial for addressing challenges like aging populations and chronic illnesses. Collaborative efforts between organizations such as Hospices Civils de Lyon and Institut TransMedTech foster the development of advanced medical technologies and sustainable solutions, enhancing care quality and economic productivity. The upcoming Entretiens Jacques Cartier symposium will further explore these partnerships and their socio-economic impacts.

ubs maintains buy rating for totalenergies with target price of 67 euros

UBS has maintained a 'Buy' rating for TotalEnergies with a target price of 67 euros, despite expectations of a weak third quarter. Analyst Henri Patricot has lowered his estimates for the oil and gas producer, indicating they fall below consensus expectations. As of October 17, TotalEnergies shares are trading at approximately 59.79 euros, reflecting a slight increase of 0.62%.
15:00 15.10.2024

UBS maintains buy rating for Totalenergies with price target of 67 euros

UBS has maintained a "Buy" rating for Totalenergies, setting a price target of 67 euros, despite expectations of a weak third quarter. Analyst Henri Patricot noted a reduction in estimates for the oil and gas producer, which he believes will fall below consensus expectations.
15:00 15.10.2024

social security financing bill aims to cut healthcare and pension costs

The Social Security Financing Bill for 2025 aims to reduce the deficit from €18 billion to €16 billion through cuts in healthcare spending and a six-month delay in pension increases. Key measures include lowering reimbursement rates for medical consultations and daily sick leave allowances, alongside negotiations to reduce costs for medical imaging and analyses. Additional provisions will enhance financial support for mental health and childcare for single-parent families.

elis expands global reach in linen and hygiene services for diverse sectors

Elis, a European leader in the rental and care of linen, workwear, and hygiene equipment, serves over 400,000 clients across various sectors, including hospitality, healthcare, and retail. By the end of 2023, the company operated 434 production and distribution centers globally. UBS continues to endorse a buy recommendation for Elis.
14:09 15.10.2024
Trending
Subcategory
Countries:
Companies:
Currencies:
People:

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Address

Newsletter

© 2025 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.